Background: (177)Lu-Dotatate, a form of Peptide Receptor Radionuclide Therapy (PRRT), was approved by FDA for treatment of somatostatin-receptor-positive NETs in 2018. Clinical trials prior to the FDA approval of (177)Lu-Dotatate showed favorable outcomes but there is limited published real world outcomes data. Methods: After obtaining IRB approval we retrospectively evaluated the efficacy of (177)Lu-Dotatate PRRT for somatostatin receptor positive gastroenteropancreatic NET patients at University of Kansas Cancer Center between June 2018 and September 2021. Results: A total of 65 patients received PRRT of which 58 completed treatment and 7 are still undergoing therapy. The 58 patients who completed treatment had a median age of 61.5 years, included 24 females and 34 males, and were 86% Caucasian and 12% black. These patients had primarily NETs of small bowel (n=24) and pancreatic (n=14) origin. Pathology showed grades 1 (21), 2 (25), and 3 (4) with a majority of well-differentiated tumors (47). All 4 treatments of PRRT were completed by 43 patients. In the entire cohort, response assessment to PRRT revealed 14 (26.9%) partial response (PR), 31 (59.6%) with stable disease (SD) and 7 (13.5%) with progressive disease (PD). In subset analysis, we found that patients with nonfunctional disease (n=29) had a higher rate of PR 42.3% vs 11.5% (p=0.0147) and higher disease control rate 96% vs 78% (p=0.042) than functional disease (n=29). Patients with nonfunctional disease had a lower PD 3.85% vs 23% (p=0.0147) and 53% vs 65% stable disease than functional disease. The table below shows clinical characteristics of these patients. Conclusions: Our real world outcomes analysis of NET treated with PRRT shows improved PR when compared to the initial clinical trials which is promising for patients. In addition, we found that there was statistically significant improved response rate in patients with non functional tumors which has not been described in literature before. If our study findings are validated in a larger cohort then it may guide patient selection for PRRT therapy in the future.